Ilan Youngster1, Erica S Shenoy2, David C Hooper2, Sandra B Nelson3. 1. Division of Infectious Diseases, Massachusetts General Hospital Harvard Medical School Division of Infectious Diseases, Boston Children's Hospital. 2. Division of Infectious Diseases, Massachusetts General Hospital Harvard Medical School Infection Control Unit, Massachusetts General Hospital, Boston, Massachusetts. 3. Division of Infectious Diseases, Massachusetts General Hospital Harvard Medical School.
Abstract
BACKGROUND: Nafcillin and cefazolin are considered first-line therapy for most infections with methicillin-susceptible Staphylococcus aureus (MSSA), and recent studies have suggested similar clinical efficacy. Limited data are available on the comparative tolerability of these agents. METHODS: In this retrospective cohort analysis of patients treated with either nafcillin or cefazolin for MSSA infection in the outpatient parenteral antimicrobial therapy clinic at Massachusetts General Hospital from 2007 to 2011, the frequency of premature antimicrobial discontinuation (PAD) and drug-emergent events (DEEs) was calculated. RESULTS: Three hundred sixty-six and 119 patients were treated with nafcillin or cefazolin, respectively. The median anticipated duration of therapy was comparable at 28 (interquartile range [IQR], 16-37) and 29 (IQR, 24-39) days, respectively, for those treated with nafcillin and cefazolin. Fewer patients completed the prespecified treatment course with nafcillin than with cefazolin (PAD rate, 33.8% vs 6.7%; P < .0001). The hazard ratio for PAD in the nafcillin vs cefazolin groups was 2.81 (95% confidence interval [CI], 1.26-3.68). More patients in the nafcillin group developed rash (13.9% vs 4.2%; P = .002), renal dysfunction (11.4% vs 3.3%; P = .006), and liver function abnormalities (8.1% vs 1.6%; P = .01). Overall rates of DEEs per 1000 patient-days were 16.9 (95% CI, 10.4-27.3) and 4.8 (95% CI, 1.1-10.2), respectively. In 9 cases of nafcillin discontinuation, treatment was changed to cefazolin; all 9 completed treatment with no further observed DEEs. CONCLUSIONS: Nafcillin treatment was associated with higher rates of both PAD as well as DEEs compared with cefazolin treatment. This difference in tolerability, in addition to efficacy and cost, should be considered when decisions for outpatient parenteral MSSA treatment are made.
BACKGROUND:Nafcillin and cefazolin are considered first-line therapy for most infections with methicillin-susceptible Staphylococcus aureus (MSSA), and recent studies have suggested similar clinical efficacy. Limited data are available on the comparative tolerability of these agents. METHODS: In this retrospective cohort analysis of patients treated with either nafcillin or cefazolin for MSSA infection in the outpatient parenteral antimicrobial therapy clinic at Massachusetts General Hospital from 2007 to 2011, the frequency of premature antimicrobial discontinuation (PAD) and drug-emergent events (DEEs) was calculated. RESULTS: Three hundred sixty-six and 119 patients were treated with nafcillin or cefazolin, respectively. The median anticipated duration of therapy was comparable at 28 (interquartile range [IQR], 16-37) and 29 (IQR, 24-39) days, respectively, for those treated with nafcillin and cefazolin. Fewer patients completed the prespecified treatment course with nafcillin than with cefazolin (PAD rate, 33.8% vs 6.7%; P < .0001). The hazard ratio for PAD in the nafcillin vs cefazolin groups was 2.81 (95% confidence interval [CI], 1.26-3.68). More patients in the nafcillin group developed rash (13.9% vs 4.2%; P = .002), renal dysfunction (11.4% vs 3.3%; P = .006), and liver function abnormalities (8.1% vs 1.6%; P = .01). Overall rates of DEEs per 1000 patient-days were 16.9 (95% CI, 10.4-27.3) and 4.8 (95% CI, 1.1-10.2), respectively. In 9 cases of nafcillin discontinuation, treatment was changed to cefazolin; all 9 completed treatment with no further observed DEEs. CONCLUSIONS:Nafcillin treatment was associated with higher rates of both PAD as well as DEEs compared with cefazolin treatment. This difference in tolerability, in addition to efficacy and cost, should be considered when decisions for outpatient parenteral MSSA treatment are made.
Authors: Douglas R Osmon; Elie F Berbari; Anthony R Berendt; Daniel Lew; Werner Zimmerli; James M Steckelberg; Nalini Rao; Arlen Hanssen; Walter R Wilson Journal: Clin Infect Dis Date: 2012-12-06 Impact factor: 9.079
Authors: Kimberly G Blumenthal; Ilan Youngster; Erica S Shenoy; Aleena Banerji; Sandra B Nelson Journal: Antimicrob Agents Chemother Date: 2014-03-17 Impact factor: 5.191
Authors: Esteban C Nannini; Martin E Stryjewski; Kavindra V Singh; Tom H Rude; G Ralph Corey; Vance G Fowler; Barbara E Murray Journal: Antimicrob Agents Chemother Date: 2010-03-08 Impact factor: 5.191
Authors: Ann L N Chapman; Simon Dixon; Dawn Andrews; Patrick J Lillie; Rohit Bazaz; Julie D Patchett Journal: J Antimicrob Chemother Date: 2009-09-19 Impact factor: 5.790
Authors: Marin L Schweizer; Jon P Furuno; Anthony D Harris; J Kristie Johnson; Michelle D Shardell; Jessina C McGregor; Kerri A Thom; Sara E Cosgrove; George Sakoulas; Eli N Perencevich Journal: BMC Infect Dis Date: 2011-10-19 Impact factor: 3.090
Authors: J Chase McNeil; Lauren M Sommer; Mary Boyle; Patrick Hogan; Jesus G Vallejo; Kristina G Hultén; Anthony R Flores; Sheldon L Kaplan; Stephanie Fritz Journal: Antimicrob Agents Chemother Date: 2020-08-20 Impact factor: 5.191
Authors: Sonia N Rao; Nathaniel J Rhodes; Benjamin J Lee; Marc H Scheetz; Amy P Hanson; John Segreti; Christopher W Crank; Sheila K Wang Journal: Antimicrob Agents Chemother Date: 2015-06-15 Impact factor: 5.191
Authors: Julius Li; Kelly L Echevarria; Darrel W Hughes; Jose A Cadena; Jason E Bowling; James S Lewis Journal: Antimicrob Agents Chemother Date: 2014-06-16 Impact factor: 5.191
Authors: J Alexander Viehman; Louise-Marie Oleksiuk; Kathleen R Sheridan; Karin E Byers; Peimei He; Bonnie A Falcione; Ryan K Shields Journal: Antimicrob Agents Chemother Date: 2016-04-22 Impact factor: 5.191